Subtyping Cutaneous Melanoma Matters

Sharouni, Mary‐Ann El; Diest, Paul J. van; Witkamp, A.J.; Sigurdsson, V.; Gils, Carla H. van

doi:10.1093/jncics/pkaa097

Cited by 22 publications

(39 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an international investigation published by Dessinioti et al, 7 20.132 NM and SSM patients with thin tumors (≤ 1 mm) were analyzed. In line with the data of El Sharouni et al, 15 they found that thin NM, particularly between 0.8 mm and 1 mm tumor thickness, were associated with worse prognosis when compared to thin SSM tumors. 15,16 By contrast, Robsahm et al 17 did not observe that NM subtype is a signi cant independent predictor for melanoma-speci c survival (n = 5010, 2008 to 2012).…”

Section: Discussionsupporting

confidence: 86%

“…In line with the data of El Sharouni et al, 15 they found that thin NM, particularly between 0.8 mm and 1 mm tumor thickness, were associated with worse prognosis when compared to thin SSM tumors. 15,16 By contrast, Robsahm et al 17 did not observe that NM subtype is a signi cant independent predictor for melanoma-speci c survival (n = 5010, 2008 to 2012). They found an insigni cant hazard ratio of 1.01 (95% CI = 0.79 to 1.29) for NM.…”

Section: Discussionsupporting

confidence: 86%

“…They observed a hazard ratio for melanoma-speci c death of 1.35 (95% CI = 1.08 to 1.70) for NM compared to SSM. By contrast, El Sharouni et al 15 studied almost 50.000 MM patients, including approximately 80% primary SSM and about 15% primary NM. They observed that NM patients with tumors greater than 1 mm tumor thickness did not show worse survival than SSM patients with tumors greater than 1 mm.…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Multivariate Analysis of Prognostic Factors in Patients With Nodular Melanoma

Susok

Stücker

Bechara

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose Nodular melanoma (NM) is associated with worse disease outcome when compared to superficial spreading melanoma (SSM). We aimed to perform a single center analysis of prognostic factors in patients with NM and compare the data with SSM patients. Methods We studied 228 patients with NN and 396 patients with SSM. Patients with in-situ melanomas or stage IV at diagnosis were not included in the study. Data were analyzed using the Mann-Whitney test, Chi² test, Kaplan-Meier curves including the log-rank test, and logistic regression model.Results When compared to patients with SSM, patients with NM had less likely lower Clark level, higher tumor thickness, less likely tumor regression, more often ulcerated tumors, and less likely a history of precursor lesions such as a nevus. Within a 5-year follow-up we observed significantly more disease relapses and deaths in NM patients than in SSM patients. On multivariate analysis, disease relapse in NM patients was independently predicted by tumor thickness and positive SLNB, whereas melanom-specific death of NM patients was independently predicted by male sex and tumor thickness. Histologic regression also remained in the logistic regression model as a significant independent negative predictor of NM death.Conclusions We did not observe that NM subtype was a significant independent predictor for disease relapse or melanoma-specific death. Among the well-known prognostic factors such as tumor thickness and male sex, NM is also associated with other unfavorable factors such as absence of regression.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Multivariate Analysis of Prognostic Factors in Patients With Nodular Melanoma

Susok

Stücker

Bechara

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In line with the data of El Sharouni et al (Sharouni et al 2020), they found that thin NM, particularly between 0.8 and 1 mm tumor thickness, were associated with worse prognosis when compared to thin SSM tumors (Sharouni et al 2020;Green et al 2012). In contrast, Robsahm et al (Robsahm et al 2018) did not observe that NM subtype is a significant independent predictor for melanoma-specific survival (n = 5010, 2008-2012).…”

Section: Discussionsupporting

confidence: 70%

“…They observed a hazard ratio for melanoma-specific death of 1.35 (95% CI = 1.08–1.70) for NM compared to SSM. In contrast, El Sharouni et al (EL Sharouni et al 2020 ) studied almost 50.000 MM patients, including approximately 80% primary SSM and about 15% primary NM. They observed that NM patients with tumors greater than 1 mm tumor thickness did not show worse survival than SSM patients with tumors greater than 1 mm.…”

Section: Discussionmentioning

confidence: 99%

Multivariate analysis of prognostic factors in patients with nodular melanoma

Susok

Stücker

Bechara

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Nodular melanoma (NM) is associated with worse disease outcome when compared to superficial spreading melanoma (SSM). We aimed to perform a single-center analysis of prognostic factors in patients with NM and compare the data with SSM patients. Methods We studied 228 patients with NN and 396 patients with SSM. Patients with in situ melanomas or stage IV at diagnosis were not included in the study. Data were analyzed using the Mann–Whitney test, Chi-square test, Kaplan–Meier curves including the log-rank test, and logistic regression model. Results When compared to patients with SSM, patients with NM had less likely lower Clark level, higher tumor thickness, less likely tumor regression, more often ulcerated tumors, and less likely a history of precursor lesions such as a nevus. Within a 5-year follow-up we observed significantly more disease relapses and deaths in NM patients than in SSM patients. On multivariate analysis, disease relapse in NM patients was independently predicted by tumor thickness and positive SLNB, whereas melanoma-specific death of NM patients was independently predicted by male sex and tumor thickness. Histologic regression also remained in the logistic regression model as a significant independent negative predictor of NM death. Conclusions We did not observe that NM subtype was per se a significant independent predictor for disease relapse or melanoma-specific death. Among the well-known prognostic factors such as tumor thickness and male sex, NM is also associated with other unfavorable factors such as absence of regression.

show abstract

Decoding the synergistic potential of MAZ‐51 and zingerone as therapy for melanoma treatment in alignment with sustainable development goals

Letsoalo,

Nortje,

Patrick

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Melanoma, an invasive class of skin cancer, originates from mutations in melanocytes, the pigment‐producing cells. Globally, approximately 132,000 new cases are reported each year, and in South Africa, the incidence stands at 2.7 per 100,000 people, signifying a worrisome surge in melanoma rates. Therefore, there is a need to explore treatment modalities that will target melanoma's signalling pathways. Melanoma metastasis is aided by ligand activity of transforming growth factor‐beta 1 (TGF‐β1), vascular endothelial growth factor‐C (VEGF‐C) and C‐X‐C chemokine ligand 12 (CXCL12) which bind to their receptors and promote tumour cell survival, lymphangiogenesis and chemotaxis. (3‐(4‐dimethylaminonaphthelen‐1‐ylmethylene)‐1,3‐dihydroindol‐2‐one) MAZ‐51 is an indolinone‐based molecule that inhibits VEGF‐C induced phosphorylation of vascular endothelial growth factor receptor 3 (VEGFR‐3). Despite the successful use of conventional cancer therapies, patients endure adverse side effects and cancer drug resistance. Moreover, conventional therapies are toxic to the environment and caregivers. The use of medicinal plants and their phytochemical constituents in cancer treatment strategies has become more widespread because of the rise in drug resistance and the development of unfavourable side effects. Zingerone, a phytochemical derived from ginger exhibits various pharmacological properties positioning it as a promising candidate for cancer treatment. This review provides an overview of melanoma biology and the intracellular signalling pathways promoting cell survival, proliferation and adhesion. There is a need to align health and environmental objectives within sustainable development goals 3 (good health and well‐being), 13 (climate action) and 15 (life on land) to promote early detection of skin cancer, enhance sun‐safe practices, mitigation of environmental factors and advancing the preservation of biodiversity, including medicinal plants. Thus, this review discusses the impact of cytostatic cancer drugs on patients and the environment and examines the potential use of phytochemicals as adjuvant therapy.

show abstract

Subtyping Cutaneous Melanoma Matters

Cited by 22 publications

References 26 publications

Multivariate Analysis of Prognostic Factors in Patients With Nodular Melanoma

Multivariate Analysis of Prognostic Factors in Patients With Nodular Melanoma

Multivariate analysis of prognostic factors in patients with nodular melanoma

Decoding the synergistic potential of MAZ‐51 and zingerone as therapy for melanoma treatment in alignment with sustainable development goals

Contact Info

Product

Resources

About